Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14157457 | 0.86 | ITGB3 (0.57) | ITGB3ITGA2BFFAR1CYP2C9TSHR | |
| SCHEMBL25832150 | 0.86 | ITGB3 (0.57) | ITGB3ITGA2BFFAR1CYP2C9TSHR | |
| SCHEMBL21991333 | 0.85 | ITGB3 (0.56) | ITGB3ITGA2BFFAR1ALDH1A1KMT2A | |
| SCHEMBL27916324 | 0.83 | ITGB3 (0.54) | ITGB3ITGA2BFFAR1CYP2C9ALDH1A1 | |
| SCHEMBL9714249 | 0.83 | FFAR1 (0.61) | ITGB3ITGA2BFFAR1 | |
| SCHEMBL1913900 | 0.82 | CACNA2D1 (0.47) | ITGB3ITGA2BFFAR1CYP2C9TSHR | |
| SCHEMBL4939316 | 0.82 | CACNA2D1 (0.47) | ITGB3ITGA2BFFAR1CYP2C9TSHR | |
| SCHEMBL4939311 | 0.82 | CACNA2D1 (0.47) | ITGB3ITGA2BFFAR1CYP2C9TSHR | |
| SCHEMBL3127511 | 0.82 | CACNA2D1 (0.47) | ITGB3ITGA2BFFAR1CYP2C9TSHR | |
| SCHEMBL5228349 | 0.82 | ITGB3 (0.53) | ITGB3ITGA2BFFAR1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | ITGB3 1766/4885ITGA2B 2436/4885FFAR1 147/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | ITGB3 1766/4885ITGA2B 2436/4885FFAR1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.